TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients
| Trial | Studied treatment | Control | Patients |
|---|
| STAMINA-HeFT (Ghali), 2008 | darbepoetin alfa SC every 2 weeks for 1 year (target hemoglobin, 14.0+/-1.0 g/dL). | placebo | Patients with symptomatic HF, left ventricular ejection fraction < or = 40%, and hemoglobin > or = 9.0 g/dL and < or = 12.5 g/dL |
| van Veldhuisen, 2007 | darbepoetin alfa subcutaneously every 2 weeks for 26 weeks at a starting weight-adjusted dose of 0.75 mcg/kg or a fixed dose of 50 mcg | placebo | Patients with chronic heart failure (>=3 months), left ventricular ejection fraction <= 40%, and Hb 9.0 to 12.5 g/dL |
| Ponikowski, 2007 | Subcutaneous (SC) Darbepoetin Alfa | subcutaneous placebo | patients with Symptomatic Congestive Heart Failure (CHF) and Anemia |
| Parissis, 2008 | 3-month darbepoetin alpha regimen at 1.5 microg/kg every 20 days plus oral iron | placebo plus oral iron | CHF patients NYHA II-III, LV ejection fraction [EF] <40%, hemoglobin level <12.5 g/dL, serum creatinine level <2.5 mg/dL |
| Parissis, 2009 | 3-month darbepoetin alfa regimen at 1.5 microg/kg every 20 days plus oral iron | placebo plus oral iron | patients with CHF (LV ejection fraction [LVEF] <40%, hemoglobin <12.5 g/dl, and serum creatinine <2.5 mg/dl |
| Kourea, 2008 | 3-month darbepoietin-alpha at 1.5 microg/Kg every 20 days plus iron orally | placebo plus iron orally | CHF patients NYHA II-III; left ventricular ejection fraction <40%; hemoglobin<12.5 g/dl; serum creatinine<2.5 mg/dl |
